Expression of the BAD pathway is a marker of triple-negative status and poor outcome
Name:
s41598-019-53695-0.pdf
Size:
3.068Mb
Format:
PDF
Description:
Final Published Version
Author
Boac, Bernadette MAbbasi, Forough
Ismail-Khan, Roohi
Xiong, Yin
Siddique, Atif
Park, Hannah
Han, Mingda
Saeed-Vafa, Daryoush
Soliman, Hatem
Henry, Brendon
Pena, M Juliana
McClung, E Clair
Robertson, Sharon E
Todd, Sarah L
Lopez, Alex
Sun, Weihong
Apuri, Susmitha
Lancaster, Johnathan M
Berglund, Anders E
Magliocco, Anthony M
Marchion, Douglas C
Affiliation
Univ Arizona, Canc Ctr, Obstet & GynecolIssue Date
2019-11-25
Metadata
Show full item recordPublisher
NATURE PUBLISHING GROUPCitation
Boac, B.M., Abbasi, F., Ismail-Khan, R. et al. Expression of the BAD pathway is a marker of triple-negative status and poor outcome. Sci Rep 9, 17496 (2019) doi:10.1038/s41598-019-53695-0Journal
SCIENTIFIC REPORTSRights
Copyright © The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Triple-negative breast cancer (TNBC) has few therapeutic targets, making nonspecific chemotherapy the main treatment. Therapies enhancing cancer cell sensitivity to cytotoxic agents could significantly improve patient outcomes. A BCL2-associated agonist of cell death (BAD) pathway gene expression signature (BPGES) was derived using principal component analysis (PCA) and evaluated for associations with the TNBC phenotype and clinical outcomes. Immunohistochemistry was used to determine the relative expression levels of phospho-BAD isoforms in tumour samples. Cell survival assays evaluated the effects of BAD pathway inhibition on chemo-sensitivity. BPGES score was associated with TNBC status and overall survival (OS) in breast cancer samples of the Moffitt Total Cancer Care dataset and The Cancer Genome Atlas (TCGA). TNBC tumours were enriched for the expression of phospho-BAD isoforms. Further, the BPGES was associated with TNBC status in breast cancer cell lines of the Cancer Cell Line Encyclopedia (CCLE). Targeted inhibition of kinases known to phosphorylate BAD protein resulted in increased sensitivity to platinum agents in TNBC cell lines compared to non-TNBC cell lines. The BAD pathway is associated with triple-negative status and OS. TNBC tumours were enriched for the expression of phosphorylated BAD protein compared to non-TNBC tumours. These findings suggest that the BAD pathway it is an important determinant of TNBC clinical outcomes.Note
Open access journalISSN
2045-2322PubMed ID
31767884Version
Final published versionSponsors
National Cancer Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1R21 CA-181617-01]; Total Cancer Care Initiative; Collaborative Data Services Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center [P30-CA076292]; DeBartolo Family; Tissue Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center [P30-CA076292]; Cancer Informatics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center [P30-CA076292]; Analytic Microscopy Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center [P30-CA076292]ae974a485f413a2113503eed53cd6c53
10.1038/s41598-019-53695-0
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.
Related articles
- Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing.
- Authors: Zhang H, Sun Y, Du X
- Issue date: 2024 Aug 19
- Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
- Authors: Liu Y, Teng L, Fu S, Wang G, Li Z, Ding C, Wang H, Bi L
- Issue date: 2021 May 31
- Integrated machine learning algorithms identify KIF15 as a potential prognostic biomarker and correlated with stemness in triple-negative breast cancer.
- Authors: Guo Q, Qiu P, Pan K, Liang H, Liu Z, Lin J
- Issue date: 2024 Sep 13
- Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
- Authors: Zhong G, Lou W, Shen Q, Yu K, Zheng Y
- Issue date: 2020 Feb
- Integrated network analysis and machine learning approach for the identification of key genes of triple-negative breast cancer.
- Authors: Naorem LD, Muthaiyan M, Venkatesan A
- Issue date: 2019 Apr